Vaccines and Biologics: Questions Remain MedPage Today Inadequate protection after influenza vaccination also has been seen among patients receiving the B-cell depleting agent rituximab (Rituxan), with particularly low responses being seen among patients whose B cells are fully depleted. Therefore, "it ... |
